Valentine-King Marissa A, Trautner Barbara W, Zoorob Roger J, Germanos George, Hansen Michael, Salemi Jason L, Gupta Kalpana, Grigoryan Larissa
Department of Family and Community Medicine, Baylor College of Medicine, Houston, Texas.
Section of Health Services Research, Department of Medicine, Baylor College of Medicine, Houston, Texas.
Antimicrob Steward Healthc Epidemiol. 2022 Jan 17;2(1):e8. doi: 10.1017/ash.2021.224. eCollection 2022.
We characterized antibiotic prescribing patterns and management practices among recurrent urinary tract infection (rUTI) patients, and we identified factors associated with lack of guideline adherence to antibiotic choice, duration of treatment, and urine cultures obtained. We hypothesized that prior resistance to nitrofurantoin or trimethoprim-sulfamethoxazole (TMP-SMX), shorter intervals between rUTIs, and more frequent rUTIs would be associated with fluoroquinolone or β-lactam prescribing, or longer duration of therapy.
This study was a retrospective database study of adult women with (ICD-10) cystitis codes meeting American Urological Association rUTI criteria at outpatient clinics within our academic medical center between 2016 and 2018. We excluded patients with ICD-10 codes indicative of complicated UTI or pyelonephritis. Generalized estimating equations were used for risk-factor analysis.
Among 214 patients with 566 visits, 61.5% of prescriptions comprised first-line agents of nitrofurantoin (39.7%) and TMP-SMX (21.5%), followed by second-line choices of fluoroquinolones (27.2%) and β-lactams (11%). Most fluoroquinolone prescriptions (86.7%), TMP-SMX prescriptions (72.2%), and nitrofurantoin prescriptions (60.2%) exceeded the guideline-recommended duration. Approximately half of visits lacked a urine culture. Receiving care through urology via telephone was associated with receiving a β-lactam (adjusted odds ratio [aOR], 6.34; 95% confidence interval [CI], 2.58-15.56) or fluoroquinolone (OR, 2.28; 95% CI, 1.07-4.86). Having >2 rUTIs during the study period and seeking care from a urology practice (RR, 1.28, 95% CI, 1.15-1.44) were associated with longer antibiotic duration.
We found low guideline concordance for antibiotic choice, duration of therapy and cultures obtained among rUTI patients. These factors represent new targets for outpatient antibiotic stewardship interventions.
我们对复发性尿路感染(rUTI)患者的抗生素处方模式和管理实践进行了特征描述,并确定了与未遵循抗生素选择、治疗时长及进行尿培养相关的因素。我们假设,既往对呋喃妥因或甲氧苄啶 - 磺胺甲恶唑(TMP - SMX)耐药、rUTI发作间隔较短以及rUTI发作频率较高与氟喹诺酮类或β - 内酰胺类药物处方或更长疗程相关。
本研究是一项回顾性数据库研究,研究对象为2016年至2018年期间在我们学术医疗中心门诊符合美国泌尿外科学会rUTI标准且有(ICD - 10)膀胱炎编码的成年女性。我们排除了具有指示复杂性UTI或肾盂肾炎的ICD - 10编码的患者。采用广义估计方程进行危险因素分析。
在214例患者的566次就诊中,61.5%的处方包含一线药物呋喃妥因(39.7%)和TMP - SMX(21.5%),其次是二线选择氟喹诺酮类(27.2%)和β - 内酰胺类(11%)。大多数氟喹诺酮类处方(86.7%)、TMP - SMX处方(72.2%)和呋喃妥因处方(60.2%)超过了指南推荐的疗程。约一半的就诊未进行尿培养。通过泌尿外科电话就诊与开具β - 内酰胺类药物(调整后比值比[aOR],6.34;95%置信区间[CI],2.58 - 15.56)或氟喹诺酮类药物(OR,2.28;95% CI,1.07 - 4.86)相关。在研究期间有>2次rUTI发作且在泌尿外科就诊(RR,1.28,95% CI,1.15 - 1.44)与抗生素疗程较长相关。
我们发现rUTI患者在抗生素选择、治疗时长及尿培养方面与指南的一致性较低。这些因素是门诊抗生素管理干预的新目标。